[Relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma].
OBJECTIVE
C-erbB2, C-erbB3, and C-erbB4 are numbers of epidermal growth factor family. It has been confirmed that C-erbB2 was related to ovarian carcinoma, but the relationship of C-erbB3 and C-erbB4 with ovarian carcinoma is unclear. The objective of this study was to explore the relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma.


METHODS
Streptavidin-peroxidase immunohistochemistry method was used to determine the expression of C-erbB2, C-erbB3, and C-erbB4 in 49 cases of ovarian malignant neoplasms, 21 cases of ovarian benign neoplasms, and 19 cases of normal ovarian tissues (control), then the relationship of expression of C-erbB2, C-erbB3, C-erbB4 and clinicopathologic parameters in ovarian neoplasm was analyzed.


RESULTS
(1) The positive expression rates of C-erbB2, C-erbB3, and C-erbB4 in ovarian malignant neoplasms were 75.51%, 69.39%, and 65.31%, respectively, and they were higher than that in ovarian benign neoplasms (19.05%, 23.81%, and 23.81%, respectively) and control (21.05%, 15.79%, and 21.05%, respectively)(P< 0.05). (2) There was not significant difference between the expression of C-erbB2, C-erbB3, and C-erbB4 in ovarian malignant neoplasms and its pathologic type and grade (P >0.05). (3) The positive expression rates of C-erbB2, C-erbB3, and C-erbB4 in the patients with late stage or large amount of ascetic volume ( >500 ml) were 90.0% and 91.3%, respectively, and those also were higher than that in early stage or ascetic volume< 500 ml (P< 0.05). (4) The cumulative survival time of the patients with positive expression of C-erbB2 or C-erbB4 was longer than that without expression (P< 0.01). The analysis of Cox model showed that expressions of C-erbB2 and C-erbB4 in ovarian malignant were also independent prognosis factors for ovarian cancer.


CONCLUSIONS
The C-erbB family would play an importation role in ovarian malignant neoplasms, and also was related to poor prognosis in ovarian cancer.
Li
Li
L
Department of Gynecologic Oncology, Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, 30021, PR China. lili_temp@hotmail.com
Zhong
Yan-Ping
YP
Zhang
Wei
W
Zhang
Jie-Qing
JQ
Yao
Zhong-Qiang
ZQ
D000293:Adolescent; D000328:Adult; D000368:Aged; D018282:Cystadenocarcinoma, Mucinous / Q000378:metabolism* / Q000556:secondary; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000556:secondary; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D016586:Granular Cell Tumor / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000378:metabolism / Q000556:secondary; D011379:Prognosis; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D020893:Receptor, ErbB-3 / Q000378:metabolism; D066247:Receptor, ErbB-4; D015996:Survival Rate
D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; C587689:ERBB4 protein, human